

UNITED NATIONS CHILDREN'S FUND (UNICEF)
AFGHANISTAN COUNTRY OFFICE, KABUL, AFGHANISTAN
REQUEST FOR EXPRESSION OF INTEREST (REoI)
FOR PHARMACEUTICAL PRODUCTS

Date of Request for Expression of Interest (REoI): **12th May 2025**

Closing date for receipt of REoI: **Multiple windows of submissions due on 1st day of every month open for 12 month starts on 1st July 2025 and ends on 1st May 2026.**

There are multiple due dates for submission: 1st of July 2025, 1st Aug 2025, 1st Sep 2025, 1st Oct 2025, 1st Nov 2025, 1st Dec 2025, 1st Jan 2026, 1st Feb 2026, 1st Mar 2026, 1st April 2026, 1st May 2026 and final due date 1st June 2026.

UNICEF, Afghanistan Country Office, Kabul, Afghanistan is requesting Expressions of Interest from potential suppliers of pharmaceuticals from Afghanistan and its neighbouring countries (India, Iran, Pakistan, China, etc.) in preparation for a solicitation exercise for pharmaceutical products.

Interested suppliers or manufacturers of pharmaceuticals, please read below the requirements and submit your expression of interest (EoI) by filling in the forms along with the documentation requested.

Purpose of the REOI:

This REoI is addressed to suppliers and manufacturers of pharmaceuticals in the region for the supply of any of the listed pharmaceutical products.

Description of requirements:

S.No	Description
1	Aminophylline 100mg tablets
2	Amoxicillin 250mg dispersible tablet
3	Amoxicillin 500mg capsules
4	Amoxicillin 500mg tablets
5	Amoxicillin 125mg/5ml pwd.o.s./BOT-100ml
6	Amoxicillin powder for oral suspension, 250mg /5ml (anhydrous)
7	Ampicillin 1g (as sodium salt) powder for injection
8	Atenolol 100 mg tablets
9	Betamethasone 0.1% + Neomycine 0.5%, topical cream
10	Ceftriaxone powder for injection/infusion 500mg
11	Chlorhexidine 7.1 % umbilical gel tube
12	Chloroquine 50mg/5ml syrup
13	Ciprofloxacin 250mg tablet
14	Compound Sodium Lactate 1L bag
15	Diazepam 5mg/ml, injection
16	Diazepam Diazepam 5mg, tablet
17	Erythromycin (Ethyl succinate) Suspension 100 mg/ml, bottles
18	Ferrous sulphate 60mg tablets
19	Gentamicin eye drops 0.3%
20	Gentamicin 10mg/ml (as sulfate), injection
21	Gentamicin 20mg/ml (as sulfate), injection
22	Hydrocortisone pdr/inj 100mg
23	Iron 60 mg+ Folic Acid 400 mcg/

24	Ketamine 50mg/ml (hydrochloride), injection
25	Lidocaine (hydrochloride) 1% + Adrenaline (epinephrine) 1:200 000, injection
26	Lidocaine (hydrochloride) 2% + Adrenaline (epinephrine) 1:200 000, injection
27	Metronidazole 400mg tablets
28	Micronutrient tabs, used during pregnancy
29	Nitrofurantoin 100mg, tablet
30	ORS fl.1Lx2+ Zinc 20mg 10tabs.kit/PAC
31	ORS low osm. flavour 20.5/1
32	Paracetamol 100mg disp. Tabs
33	Paracetamol 120mg/5ml o.s/BOT-60ml
34	Paracetamol 500mg tabs
35	Phenobarbital 100mg tabs
36	Phenobarbital 200mg/ml
37	Phenobarbital 15mg tabs
38	Phenoxymethylpenicillin (Penicillin V) 500mg (as potassium-salt), tablet
39	Phenoxymethylpenicillin (Penicillin V) 250mg (as potassium-salt), tablet
40	Salbutamol 2mg/5ml oral liquid/BOT-100ml
41	Salbutamol 4mg tablets
42	Salbutamol 5mg/2.5ml Neb sol. amp
43	Salbutamol inhalation (aerosol) 0.1 mg (sulfate) per dose, 200 doses/inhaler
44	Sodium Chloride 0.9 % w/v and Glucose 5% w/v solution
45	Sul.200mg+Trim.40mg/5ml or.sus/BOT-100ml
46	Sulf.100mg+Trimet.20mg disp.tab
47	Sulf.400mg+Trimet.80mg tabs
48	Suxamethonium inj/50mg/ml/2ml
49	Tetracycline eye ointment 1%/TBE-5g
50	Tramadol 100mg/2ml, injection
51	Zinc 20 mg scored disp. Tablets

For an itemised list of products per category, please refer to the accompanying Expression of Interest (EoI) form.

Historical procurement data (2023-2024):

S.No	Description	Estimated Value (USD)
1	Aminophylline 100mg tablets	18,437
2	Amoxicillin 250mg dispersible tablet	1,672,725
3	Amoxicillin 500mg capsules	2,108,064
4	Amoxicillin 500mg tablets	2,108,064
5	Amoxicillin 125mg/5ml pwd.o.s./BOT-100ml	1,481,150
6	Amoxicillin powder for oral suspension, 250mg /5ml (anhydrous)	121,423
7	Ampicillin 1g (as sodium salt) powder for injection	270,135
8	Atenolol 100 mg tablets	4,880
9	Betamethasone 0.1% + Neomycine 0.5%, topical cream	10,484
10	Ceftriaxone powder for injection/infusion 500mg	806,800
11	Chlorhexidine 7.1 % umbilical gel tube	269,364

12	Chloroquine 50mg/5ml syrup	2,084
13	Ciprofloxacin 250mg tablet	153,846
14	Compound Sodium Lactate 1L bag	2,130,006
15	Diazepam 5mg/ml, injection	56,765
16	Diazepam Diazepam 5mg, tablet	36,175
17	Erythromycin (Ethyl succinate) Suspension 100 mg/ml, bottles	958,149
18	Ferrous sulphate 60mg tablets	2,596
19	Gentamicin eye drops 0.3%	437,875
20	Gentamicin 10mg/ml (as sulfate), injection	70,955
21	Gentamicin 20mg/ml (as sulfate), injection	35,300
22	Hydrocortisone pdr/inj 100mg	230,931
23	Iron 60 mg+ Folic Acid 400 mcg/	689,949
24	Ketamine 50mg/ml (hydrochloride), injection	181,356
25	Lidocaine (hydrochloride) 1% + Adrenaline (epinephrine) 1:200 000, injection	3,904
26	Lidocaine (hydrochloride) 2% + Adrenaline (epinephrine) 1:200 000, injection	32,073
27	Metronidazole 400mg tablets	538,905
28	Micronutrient tabs, used during pregnancy	1,265,735
29	Nitrofurantoin 100mg, tablet	84,850
30	ORS fl.1Lx2+ Zinc 20mg 10tabs.kit/PAC	2,620,881
31	ORS low osm. flavour 20.5/1	604,819
32	Paracetamol 100mg disp. Tabs	623,150
33	Paracetamol 120mg/5ml o.s/BOT-60ml	588,195
34	Paracetamol 500mg tabs	1,581,242
35	Phenobarbital 100mg tabs	19,783
36	Phenobarbital 200mg/ml	26,074
37	Phenobarbital 15mg tabs	62,520
38	Phenoxymethylpenicillin (Penicillin V) 500mg (as potassium-salt), tablet	333,761
39	Phenoxymethylpenicillin (Penicillin V) 250mg (as potassium-salt), tablet	317,155
40	Salbutamol 2mg/5ml oral liquid/BOT-100ml	144,295
41	Salbutamol 4mg tablets	27,523
42	Salbutamol 5mg/2.5ml Neb sol. amp	25,162
43	Salbutamol inhalation (aerosol) 0.1 mg (sulfate) per dose, 200 doses/inhaler	280,408
44	Sodium Chloride 0.9 % w/v and Glucose 5% w/v solution	747,634
45	Sul.200mg+Trim.40mg/5ml or.sus/BOT-100ml	508,166
46	Sulf.100mg+Trimet.20mg disp.tab	682,288
47	Sulf.400mg+Trimet.80mg tabs	983,720
48	Suxamethonium inj/50mg/ml/2ml	54,929
49	Tetracycline eye ointment 1%/TBE-5g	826,189
50	Tramadol 100mg/2ml, injection	18,495
51	Zinc 20 mg scored disp. Tablets	292,535

Potential suppliers/manufacturers:

UNICEF primarily globally purchases pharmaceuticals directly from manufacturers and/or their authorized representatives.

UNICEF Afghanistan is particularly interested in identifying GMP qualified manufacturers with a Good Manufacturing Practice (GMP) Certificate issued by any stringent regulatory authority, PICS member or

any of the following agencies: WHO, UNICEF, MSF or ICRC and/or suppliers with a Good Distribution Licence (GDP) for Medicines who procure & distribute pharmaceuticals from GMP qualified manufacturers for the items listed below for Afghanistan.

Potential suppliers/manufacturers are to indicate for the products of interest, all the packaging types and pack sizes they have available in their portfolios.

To be considered for the planned tender it is preferable, but not a requirement, for potential suppliers to have a website providing access to the product information if available, and in addition to provide information as per Annex I and Annex II below.

Please also provide information on the registration status of the medicines specifically in Afghanistan in addition to the other countries of registration of such as India, Pakistan, China, United Kingdom, European Union, United States of America, Australia or Canada etc.

Procedure for submission of EoI:

Interested suppliers/manufacturers are encouraged to indicate their interest by duly completing the Expression of Interest (EoI) form (Annex I) and the [Additional template for REOI-HER \(Annex II\)](#) and submit via email to: afghanistanetendering@unicef.org with the subject **Expression of Interest (EoI) for Pharmaceutical products.**

Please note:

- (a) Prices are not required at this stage.
- (b) Questions from manufacturers/suppliers on any aspects of their products included in the submission will not be entertained.
- (c) This REoI does not constitute a solicitation. Submitting an EoI does not automatically guarantee receipt of the solicitation document when it will eventually be issued.
- (d) UNICEF reserves the right, when issuing the final solicitation document, to request from the interested manufacturers/supplier's compliance to additional conditions.

UNICEF reserves the following rights:

- (a) to seek additional information deemed as appropriate for evaluation of the EoIs.
- (b) to accept any submission for this expression of interest, in whole or in part; to reject any or all submissions for this expression of interest; or to cancel this EoI process in its entirety.
- (c) to verify any information contained in the EoI response (and the submitter will provide UNICEF with its reasonable cooperation with such verification).
- (c) to invalidate any submission to this EoI that, in UNICEF's sole opinion, fails to meet the requirements and instructions as stated in this Request for Expression of Interest.
- (e) UNICEF is not liable for any costs/expenses or loss incurred by interested suppliers and manufacturers in connection with responding to this Request for Expression of Interest

Registration on the United Nations Global Marketplace (UNGM)

Interested manufacturers/suppliers are encouraged to register on the United Nations Global Market Place (UNGM) website through the link <https://www.ungm.org/> to receive various tender alerts issued by United Nations.

ANNEX I: EXPRESSION OF INTEREST FORM

(Please check the appropriate boxes and return to UNICEF)

A - GENERAL INFORMATION

Supplier's full name:			
Type of company	Manufacturer <input type="checkbox"/>	Wholesaler <input type="checkbox"/>	Other(specify) <input type="checkbox"/>
Address:			
Country:			
Email address (company):			
Website address:			
Telephone:			
Fax:			
Contact person:			
E-mail address for contact person:			

B – INTEREST / CAPACITY TO SUPPLY THE FOLLOWING CATEGORIES

Please see link to UNICEF technical requirements for Pharmaceutical and Nutrition Products:

[UNICEF Technical Requirements for pharmaceuticals 5th edition 2017 for additional information](#)

Medicine	Yes	No	In this column, please specify following: • Packaging type and pack size you would like to offer.
1- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
2- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
3- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
4- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
5- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
6- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
7- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
8- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
9- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
10- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
11- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	
12- Name of medicine	<input type="checkbox"/>	<input type="checkbox"/>	

C – GEOGRAPHICAL COVERAGE

	Yes	No	Any limitation, please explain
Ability to supply to UNICEF Afghanistan	<input type="checkbox"/>	<input type="checkbox"/>	
Are you authorized by AFDA to supply medicines and pharmaceutical products in Afghanistan	<input type="checkbox"/>	<input type="checkbox"/>	
Do you have an authorized representative approved by AFDA to supply medicines and pharmaceutical products in Afghanistan	<input type="checkbox"/>	<input type="checkbox"/>	

D - COMPLIANCE WITH INTERNATIONAL QUALITY STANDARDS

Quality Management System (company):	Yes	No	Comments
Valid GMP certificate issued by regulatory authority as per WHO Good Manufacturing Practice (GMP) Guidelines (please indicate name of regulatory authority) https://www.who.int/publications/m/item/trs986-annex2	<input type="checkbox"/>	<input type="checkbox"/>	
GMP inspection by Stringent Regulatory Authority in the last 5 years https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2	<input type="checkbox"/>	<input type="checkbox"/>	

GMP inspection by PICS member in the last 5 years Members (picscheme.org) Please indicate name of PICs member (s)	<input type="checkbox"/>	<input type="checkbox"/>	
GMP inspections/audits by MSF, ICRC, UNICEF in the last 5 years Please indicate name of Agency(s)	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	
Others-specify	<input type="checkbox"/>	<input type="checkbox"/>	

E – ACCESS TO PRODUCT INFORMATION

	Yes	No	
Product information (SmPC) available on-line	<input type="checkbox"/>	<input type="checkbox"/>	If Yes, specify web address:
Product catalogue available on-line	<input type="checkbox"/>	<input type="checkbox"/>	If Yes, specify web address:
Any other ways of providing access to product information	<input type="checkbox"/>	<input type="checkbox"/>	If Yes, specify which way(s):

F- ADDITIONAL INFORMATION

	Yes	No		Yes	No
Registered with UNGM? (www.ungm.org)	<input type="checkbox"/>	<input type="checkbox"/>	UNGM number		
UNICEF vendor	<input type="checkbox"/>	<input type="checkbox"/>	UNICEF vendor number		

G – COMMITMENT TO SUSTAINABILITY IN PROCUREMENT SDG GOAL 12 AND ITS TARGET 12.7

Please provide company policy as applicable for below criteria

#	Criteria	Indicators
1	Prevention of pollution	Corporate environmental policy or an environmental management system (ISO 14001 or equivalent)
2	Sustainable resource use	Company policy on design and production to use recycled, recyclable, biodegradable, re-used, reusable, renewable or compostable materials
3	Social inclusion of persons with disabilities	The requirement has been reviewed and potentially adapted to ensure accessibility for persons with disabilities
4	Human rights and Gender issues	Company policy on human rights issues and reserved procurement opportunities (lot, subcontract, or entire tender) open to vendors qualifying as women-owned businesses, i.e. an entity at least 51% owned, managed and controlled by one or more women
5	Social health and well-being	- Avoidance of chemicals potentially hazardous to users of the product, like volatile organic compounds (VOCs) etc. - Require labelling of included/used hazardous chemicals

On completion, please return this form to UNICEF including the Summary of Pharmaceutical Characteristics (SPC) for each item offered by email to afghanistanetendering@unicef.org starting from 1st day of each month beginning of July 2024.

ANNEX II: [ADDITIONAL TEMPLATE FOR REOI-HER](#)

UNICEF Afghanistan Country Office	
REQUEST FOR EXPRESSION OF INTEREST	
Pharmaceuticals	
(Complete one form for each separate product)	
Date	
Name of company	
Type of Company (manufacturer/Importer/Wholesaler)	
Contact detail of person filling this form	
Name	
Title	
Email address	
Phone number	
General information about the product	
Full INN/Generic name of the product	
Brand/trade name (If any)	
Pharmaceutical form	
Strength (per dosage unit)	
Pack type and sizes	
Storage temperature	-
Transport temperature (if different from storage temperatures)	
Product shelf life	
In use Shelf life if applicable (Specify at what storage conditions)	
Language of label/Patient information leaflet (PIL)	
Full name of the FPP manufacturer	
FPP Manufacturing site (Physical address - not P O Box)	
Technical criteria	Yes/No
WHO prequalification	
Product approval by Stringent Regulatory Authority (SRA)	

If above conditions are not met then is the product manufactured at a site that is compliant with all standards of Good Manufacturing Practice (GMP) that apply to the relevant product formulation, as verified after inspection by the WHO Prequalification Programme OR an SRA OR UNICEF or a regulatory authority participating to the Pharmaceutical Inspection Cooperation Scheme (PIC/S) https://www.picscheme.org/en/members	
Bioequivalence studies or Comparative dissolution studies carried out against an approved comparator product	
Others specify anything related to certification or approval	
Market approval and product quality references	
Product complies with WHO guidelines (Y/N) https://extranet.who.int/prequal/content/WHOguidance-documents	
Product quality assurance in accordance with ICH quality guidelines (Y/N) http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html	
Compliance to BP, USP, Ph.Int, Ph.Eur for FPP and API (Specify)	
Product dossier available in appropriate format e.g. CTD (Y/N)	
Marketing Authorization Reference from country of origin/manufacture (Number, agency and country)	
Marketing Authorization Reference from other countries (Number, agency and country)	
The product registered in other countries (number, agency...)	
Others (Specify)	
Documents to submit	
Summary of Product Characteristics	Please attach
Artwork of packaging and label or pictures of the commercial product showing all sides-both primary and secondary pack.	Not mandatory at this stage but useful
GMP certificate issued by regulatory authority for the manufacturer of this product	Please attach
Market authorization certificates	Please attach